Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1083523

registered interest
date	07/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Smoking: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the NHS rollout of lung cancer scanning programmes, what assessment he has made of the effectiveness of smoking cessation methods.
tabling member constituency	Mansfield
tabling member printed	Ben Bradley
uin	229719
answer	answer is ministerial correction date of answer 15/03/2019 answer text <p>The evidence is clear that expert face-to-face support from a local stop smoking service, combined with stop smoking aids, is the most effective quitting method. People who get this support are up to four times as likely to stop smoking successfully as those who try to quit unaided. This evidence can be viewed at the following link:</p><p> </p><p><a href="http://www.ncsct.co.uk/publication_Stop_smoking_services_impact_on_quitting.php" target="_blank">http://www.ncsct.co.uk/publication_Stop_smoking_services_impact_on_quitting.php</a></p><p> </p><p>Local authorities in England are responsible for commissioning stop smoking services that meet the identified need in their areas and are targeted at the people who need it most.</p><p> </p><p>NHS England published the Standard Protocol for the Targeted Lung Health Check programme which says participants will be asked about their smoking habits when they attend a lung health check, and offered smoking cessation advice and treatment. This programme can be viewed at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/publication/targeted-screening-for-lung-cancer/" target="_blank">https://www.england.nhs.uk/publication/targeted-screening-for-lung-cancer/</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/03/2019 12:27:55 answering member 4067 label Biography information for Steve Brine
tabling member	4663 label Biography information for Ben Bradley

1083525

registered interest
date	07/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent steps he has taken to widen access to blood glucose monitoring technology for diabetes patients.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	229721
answer	answer is ministerial correction date of answer 15/03/2019 answer text <p>Glucose monitoring technology, such as continuous glucose monitoring or blood glucose test strips, will continue to be available to those meeting the relevant clinical criteria.</p><p> </p><p>In November 2018, NHS England announced that it will ensure that flash glucose monitoring is available on prescription for all patients who qualify for it in line with current recommendations. From April 2019, all qualifying patients will be able to receive it from their local general practitioner or diabetes team.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/03/2019 12:24:05 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

1083618

registered interest
date	07/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the reduction in Category M prices and the single activity fee on the financial sustainability of community pharmacies.
tabling member constituency	Greenwich and Woolwich
tabling member printed	Matthew Pennycook
uin	229774
answer	answer is ministerial correction date of answer 15/03/2019 answer text <p>The overall funding for the community pharmacy contractual framework (CPCF) has not been reduced since 2017/18 and remains at £2.592 billion for 2018/19. The Department ensures delivery of this amount by adjusting the fees paid for services and the reimbursement paid for products throughout the year. Where there is over or under payment we make appropriate adjustment to either fees or product reimbursement (typically those in Category M) to address the difference. The impact assessment for the current CPCF funding is at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/community-pharmacy-reforms" target="_blank">https://www.gov.uk/government/publications/community-pharmacy-reforms</a></p><p> </p><p>The current recovery of excess medicine margin at £10 million per month, as agreed by the Pharmaceutical Services Negotiating Committee, ceases at the end of March 2019.</p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/03/2019 13:25:59 answering member 4067 label Biography information for Steve Brine
tabling member	4520 label Biography information for Matthew Pennycook

1083653

registered interest
date	07/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dermatology
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect on patient care of reforms to dermatology services at Northern Lincolnshire and Goole NHS Foundation Trust; and what plans his Department has to improve the effectiveness and availability of dermatology services throughout the UK.
tabling member constituency	Cleethorpes
tabling member printed	Martin Vickers
uin	229669
answer	answer is ministerial correction date of answer 15/03/2019 answer text <p>No assessment has been made. The commissioning and configuration of dermatology services in England is a local matter. The local National Health Service is best placed to make decisions that ensure services meet the needs of resident populations in the most appropriate way. Health is a devolved matter, and as such, dermatology services in Wales, Scotland and Northern Ireland are a matter for the devolved administrations.</p><p> </p><p>The majority of patients with dermatological disorders are managed in primary and community care. Whilst some patients may be referred for outpatient care, data collection here is not mandated, and is therefore partial and incomplete. Furthermore, the data that is available reports episodes of care, which are not a count of patients, as the same patient may have multiple episodes of care for the same reason.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 229670 question first answered 15/03/2019 12:23:13 answering member 4067 label Biography information for Steve Brine
tabling member	3957 label Biography information for Martin Vickers

1083654

registered interest
date	07/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dermatology
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many patients with (a) psoriasis, (b) atopic dermatitis and (c) hidradenitis suppurativa were seen by a dermatologist in 2018 in (i) Northern Lincolnshire and Goole NHS Foundation Trust and (ii) nationally.
tabling member constituency	Cleethorpes
tabling member printed	Martin Vickers
uin	229670
answer	answer is ministerial correction date of answer 15/03/2019 answer text <p>No assessment has been made. The commissioning and configuration of dermatology services in England is a local matter. The local National Health Service is best placed to make decisions that ensure services meet the needs of resident populations in the most appropriate way. Health is a devolved matter, and as such, dermatology services in Wales, Scotland and Northern Ireland are a matter for the devolved administrations.</p><p> </p><p>The majority of patients with dermatological disorders are managed in primary and community care. Whilst some patients may be referred for outpatient care, data collection here is not mandated, and is therefore partial and incomplete. Furthermore, the data that is available reports episodes of care, which are not a count of patients, as the same patient may have multiple episodes of care for the same reason.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 229669 question first answered 15/03/2019 12:23:13 answering member 4067 label Biography information for Steve Brine
tabling member	3957 label Biography information for Martin Vickers

1083656

registered interest
date	07/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Inflammatory Bowel Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the savings accrued to the public purse by North Lincolnshire Care Commissioning Group as a result of the implementation of Yorkshire and Humber AHSN’s improved faecal calprotectin pathway for diagnosis of Inflammatory Bowel Disease; and if he will make a statement.
tabling member constituency	Cleethorpes
tabling member printed	Martin Vickers
uin	229672
answer	answer is ministerial correction date of answer 15/03/2019 answer text <p>No estimate has been made. The National Institute for Health and Care Excellence (NICE) recommends faecal calprotectin testing as an option to help doctors distinguish between inflammatory bowel diseases (IBDs), such as Crohn’s disease and ulcerative colitis, and non-IBDs, such as irritable bowel syndrome.</p><p> </p><p>The NICE IBD Quality Standard states that general practitioners (GP) and GP practices should ensure that testing is offered and clinical commissioning groups should ensure the diagnostic services are in place to support this.</p><p> </p><p>NHS England has produced a consensus guidance document that supports implementation of the NICE guidance. Both the guidance and statement can be found at the following link:</p><p> </p><p><a href="http://www.nice.org.uk/guidance/dg11/resources/endorsed-resource-the-use-of-faecal-calprotectin-in-primary-care-as-a-decision-diagnostic-for-inflammatory-bowel-disease-and-irritable-bowel-syndrome-4595859613" target="_blank">www.nice.org.uk/guidance/dg11/resources/endorsed-resource-the-use-of-faecal-calprotectin-in-primary-care-as-a-decision-diagnostic-for-inflammatory-bowel-disease-and-irritable-bowel-syndrome-4595859613</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/03/2019 13:37:36 answering member 4067 label Biography information for Steve Brine
tabling member	3957 label Biography information for Martin Vickers

1083686

registered interest
date	07/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many patients have been prescribed cannabis-based products for medicinal use; and how many were (a) private prescriptions and (b) prescriptions funded by NHS or NHS Scottish.
tabling member constituency	Kilmarnock and Loudoun
tabling member printed	Alan Brown
uin	229804
answer	answer is ministerial correction date of answer 12/03/2019 answer text <p>NHS England has set up systems to monitor the prescribing of cannabis-based products for medicinal use via the NHS Business Services Authority and NHS England Controlled Drugs Accountable Officers. We expect the first data to be available by the end of March 2019. In Scotland, work is underway to establish similar systems.</p><p> </p><p>There are 95,532 specialist doctors registered on the General Medical Council’s Specialist Register. The law allows any specialist doctor to prescribe cannabis-based products for medicinal use. Specialist doctors may decide to prescribe these products on a case-by-case basis, and where it is clinically appropriate. The Department does not hold information on how many of those practitioners operate private practices and are National Health Service or NHS Scotland employees or where they work.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 229805 question first answered 12/03/2019 16:17:58 answering member 4067 label Biography information for Steve Brine
tabling member	4470 label Biography information for Alan Brown

1083687

registered interest
date	07/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many medical practitioners are registered to prescribe cannabis-based products for medicinal use; how many of those practitioners (a) operate private practices and (b) are NHS or NHS Scotland employees; and if he will list the (i) Trusts and (ii) Health boards at which each of those NHS and NHS Scotland employee works.
tabling member constituency	Kilmarnock and Loudoun
tabling member printed	Alan Brown
uin	229805
answer	answer is ministerial correction date of answer 12/03/2019 answer text <p>NHS England has set up systems to monitor the prescribing of cannabis-based products for medicinal use via the NHS Business Services Authority and NHS England Controlled Drugs Accountable Officers. We expect the first data to be available by the end of March 2019. In Scotland, work is underway to establish similar systems.</p><p> </p><p>There are 95,532 specialist doctors registered on the General Medical Council’s Specialist Register. The law allows any specialist doctor to prescribe cannabis-based products for medicinal use. Specialist doctors may decide to prescribe these products on a case-by-case basis, and where it is clinically appropriate. The Department does not hold information on how many of those practitioners operate private practices and are National Health Service or NHS Scotland employees or where they work.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 229804 question first answered 12/03/2019 16:17:58 answering member 4067 label Biography information for Steve Brine
tabling member	4470 label Biography information for Alan Brown

1083696

registered interest
date	07/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tomography: Procurement
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 6 March 2019 to Question 227413 on Tomography: Inhealthcare, what the timescale was for the procurement process for PET-CT scanning services in 2017-18.
tabling member constituency	Oxford West and Abingdon
tabling member printed	Layla Moran
uin	229811
answer	answer is ministerial correction date of answer 12/03/2019 answer text <p>The Phase II PET-CT Scanning Services procurement commenced on 10 July 2017 and 10 of the 11 contracts are expected to be awarded in the next four weeks. The exception to this is Lot 4, covering the Thames Valley - Buckinghamshire, Oxfordshire and Berkshire West area, where discussions between the parties involved are still underway.</p><p> </p><p>NHS England has undertaken two phases of procurement for PET-CT services in England, the first completed during 2014-15 and the second is nearing completion. In both cases, NHS England either has or is on-track to secure significantly improved value, both in the form of additional capital investment into new scanners and new scanning locations, and in terms of reduced price to NHS England. As the Phase II process is still underway, it is not possible to make a final assessment of the cost of procurement. However, these will represent a small proportion of the overall forecast benefits.</p><p> </p><p>NHS England undertook a public engagement process between January and February 2016 which was designed to test the phase II procurement approach. The results of this process were incorporated into the final procurement design over the course of 2016/17. A thematic report of the response to public engagement was published in 2017, shortly before the phase II procurement commenced. The report can be found at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2017/04/pet-ct-engagement-report-april-2017.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2017/04/pet-ct-engagement-report-april-2017.pdf</a></p><p> </p><p>NHS England intends to undertake any further required public involvement duties in respect of planned changes in the location of services following completion of the procurement and in accordance with its responsibilities as described in section 13Q of the NHS Act 2006.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 229812 229815 question first answered 12/03/2019 16:20:00 answering member 4067 label Biography information for Steve Brine
tabling member	4656 label Biography information for Layla Moran

1083709

registered interest
date	07/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tomography: Procurement
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 6 March 2019 to Question 227413 on Tomography: Inhealthcare, what estimate he has made of the cost to the public purse of the procurement process for PET-CT scanning services in England.
tabling member constituency	Oxford West and Abingdon
tabling member printed	Layla Moran
uin	229812
answer	answer is ministerial correction date of answer 12/03/2019 answer text <p>The Phase II PET-CT Scanning Services procurement commenced on 10 July 2017 and 10 of the 11 contracts are expected to be awarded in the next four weeks. The exception to this is Lot 4, covering the Thames Valley - Buckinghamshire, Oxfordshire and Berkshire West area, where discussions between the parties involved are still underway.</p><p> </p><p>NHS England has undertaken two phases of procurement for PET-CT services in England, the first completed during 2014-15 and the second is nearing completion. In both cases, NHS England either has or is on-track to secure significantly improved value, both in the form of additional capital investment into new scanners and new scanning locations, and in terms of reduced price to NHS England. As the Phase II process is still underway, it is not possible to make a final assessment of the cost of procurement. However, these will represent a small proportion of the overall forecast benefits.</p><p> </p><p>NHS England undertook a public engagement process between January and February 2016 which was designed to test the phase II procurement approach. The results of this process were incorporated into the final procurement design over the course of 2016/17. A thematic report of the response to public engagement was published in 2017, shortly before the phase II procurement commenced. The report can be found at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2017/04/pet-ct-engagement-report-april-2017.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2017/04/pet-ct-engagement-report-april-2017.pdf</a></p><p> </p><p>NHS England intends to undertake any further required public involvement duties in respect of planned changes in the location of services following completion of the procurement and in accordance with its responsibilities as described in section 13Q of the NHS Act 2006.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 229811 229815 question first answered 12/03/2019 16:20:01 answering member 4067 label Biography information for Steve Brine
tabling member	4656 label Biography information for Layla Moran